PARP and DDR Pathway Drug Discovery Exploring cancer therapy through DNA damage response (DDR) research? DDR is key for DNA repair and preventing genomic instability. Defects in this pathway can lead to cancer. Targeting kinases like WEE1, DNA PK, ATM/ATR, and PARP proteins is crucial in drug discovery. Promega offers advanced assays and technologies for PARP/DDR pathway research, including target engagement and cell health assays. Want to learn more? Visit: https://bit.ly/3OQWwyU #kinases #PARP #assays
Promega Ireland’s Post
More Relevant Posts
-
Shornale Akter et al. analyzed RNAseq datasets of breast cancer using computational biology approach. Analyses identified several biomarkers (e.g., hsa-miR-16-5p & FOXC1) involved in cancer cell proliferation, migration, etc., & candidate compounds that can be used as repurposed drugs. Full text: https://lnkd.in/gENB4v9a #CancerReports #Wiley #BreastCancer #Transcriptome #Datasets #Biomarkers #Bioinformatics #DrugRepurposing
-
-
Identifying extracellular vesicle lncRNAs as circulating cancer biomarkers: in this review article, Panagiotis Papoutsoglou and Antonin Morillon at Institut Curie aimed to advance understanding of the functional roles of extracellular vesicles and their non-coding RNA cargo in cancer progression, emphasising the potential of EV RNA as novel diagnostic and prognostic biomarkers https://lnkd.in/g9mSntnQ The study also addresses recent technological advances and challenges in identifying EV RNA, assessing its integrity, and preserving its functionality for clinical applications. #extracellularvesicles #exosomes #biomarkers #tumorgenesis #Vesiculab
-
-
#CancerResearch antibodies help map altered pathways in tumor cells, leading to new diagnostic markers and treatment targets. As you unravel cancer's metabolic secrets, quality antibodies remain key to discoveries. View our catalog here: https://lnkd.in/eubmmk9P #research #biotech #phdlife
-
-
Genialis UPDATE 🔊: A first-in-class, RNA-based biomarker that will transform #KRAS G12C inhibitor response stratification in #NSCLC patients will be launched at #AACR. Curious about efficacy? DM me. #precisionmedicine #RNA #cancer #oncology #AI #machinelearning #clinicaldevelopment #clinicaltrials #drugdevelopment #precisiononcology
Which would you trust more for navigating treatment decisions? a) A 𝘀𝗶𝗻𝗴𝗹𝗲 𝗮𝗻𝗮𝗹𝘆𝘁𝗲🧬 (like mutation status) or b) A next-generation biomarker crafted from 𝗺𝘂𝗹𝘁𝗶𝗺𝗼𝗱𝗮𝗹 𝗱𝗮𝘁𝗮🎯 that reflects a patient’s unique biology? Genialis excels at the latter and we’re applying our chops to tackle the challenge of enhancing the rate and durability of patient responses to targeted KRAS therapeutics. Circle 𝗔𝗽𝗿𝗶𝗹 𝟵𝘁𝗵 on your calendar and meet us at the American Association for Cancer Research Annual Meeting (#AACR24) - abstract no. 6446. 🤝
-
-
Capture customized insights for #tumor genomic profiling with new Agilent Technologies SureSelect Cancer Custom panels, designed using the simple, intuitive Agilent SureDesign web portal. Tune into this webinar to learn how to design #NGS cancer assays tailored to your research goals, including the addition of new and emerging #biomarkers. https://bit.ly/4apq52y
-
-
Choosing the right models for our new TumorGraft3D 100 Model Screen is crucial for a successful study. Explore Champions’ Lumin platform to access extensive multi-omic datasets that can assist in selecting the best models. Leverage the Target and Biomarker Discovery tool to pinpoint models that demonstrate sensitivity or resistance to a specific standard of care drug, and identify genetic markers of response to the treatment. By using these markers, you can identify other models with similar responses to the drug. Powered by Lumin, access now: https://hubs.li/Q02p-DCP0 Enroll in our new TumorGraft3D 100 Model Screen: https://hubs.li/Q02p-x0f0 #PoweredByLumin #Omics #Multiomics #Biomarker #TumorGraft3D #Lumin #Genes #OncologyResearch #CancerResearch #Oncology #Cancer #Bioinformatics #organoid
-
-
Democratizing Bioinformatics for a Smarter, Healthier Future!
From target discovery to high-throughput screening, single-cell technologies are transforming every stage of cancer drug development. 💊 🔬 Shandong University researchers highlight the critical role of single-cell technologies in advancing cancer drug discovery and development. These tools offer unprecedented insights at the cellular level, which could lead to more effective cancer therapies. Discover More: https://lnkd.in/gWs4m_CG #bioinformatics #cancer #cancerresearch #singlecelltech #drugdevelopment #scRNAseq #transcriptomics #omics #spatialomics #pharmacokinetics #CRISPR #sciencenews
-
-
Calling all #biopharma researchers! Looking for new cancer drug candidates? Need trusted genomic data to validate targets? Compiling data for clinical trial design?? Look no further! COSMIC and HSMD are here to supercharge your research efforts. These expert-curated somatic databases are your keys to unlocking fast, cost-effective, and precise cancer #drugdiscovery and development. Special offer: Click here to learn more, get a free trial, plus free sample data https://buff.ly/3Vqw6Z4 QIAGEN Digital Insights
-
-
IO therapies have transformed the care of patients with cancer, but these studies present real challenges. In this white paper, IQVIA Biotech’s Erin Finot, MS, MBA explores how teaming with an experienced CRO can help sponsors successfully develop IO therapies for patients with cancer, while reducing risk. Read now. https://bit.ly/4bIwZSB #oncology #immunooncology #clinicalresearch #immunotherapy
